2022. 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s78. DOI:https://doi.org/10.25251/skin.6.supp.78.